Latest Meridian Bioscience Inc (VIVO) Headlines
Post# of 41
Posted On: 03/13/2014 4:00:49 AM
Latest Meridian Bioscience Inc (VIVO) Headlines
Shares of VIVO Down 13.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 12, 9:59AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 2 months, Meridian Bioscience has returned 13.76% as of today's recent price of $21.88.
Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018 Out Now
M2 - Fri Mar 07, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/4hmks6/global_isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018" report to their offering. The analysts forecast the Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the technological advances being made in this domain. The Global Isothermal Nucleic Acid Amplification Technologies market has also been witnessing an increase in the miniaturization of nucleic acid-based diagnostics. However, the tough competition from PCR-based diagnostics could pose a challenge to the growth of this market. The key vendors dominating this space are Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Corp. The other vendors mentioned in the report are Alere Inc., Axxin Pvt Ltd., Eiken Chemical Co. Ltd., Great Basin Corp., Lucigen Corp., Meridian Bioscience Inc., New England Biolabs Inc., and Optigene Ltd. Commenting on the report, an analyst from the team said: The Molecular Diagnostics industry is experiencing a rapid shift toward an increase in the process automation and integration of sample analysis in single miniaturized devices. Miniaturization offers scope for reduced sample volume, enabling the end-user to automate and analyze the sample. Among all the diagnostic methods, nucleic acid testing remains the method with the most potential for conducting analysis in miniaturized devices. Although PCR is one of the standard techniques for conducting amplification reaction, the method is quite complex due to the need for repeated thermo cycling and cooling, and it consumes more energy in the process. As an alternative to PCR, isothermal nucleic amplification circumvents the need for repeated denaturation and cooling as the amplification reaction occurs under isothermal conditions. This greatly aids in the design of microfluidic chips for conducting molecular diagnostics. Most of these microfluidic devices adopting isothermal nucleic acid amplification methods are in the R&D phase. It is expected that the increase in miniaturization of nucleic acid-based diagnostics will boost the growth of the market. For more information visit http://www.researchandmarkets.com/research/4h...isothermal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
19.5% Return Seen to Date on SmarTrend Meridian Bioscience Call (VIVO)
Comtex SmarTrend(R) - Tue Mar 04, 5:24PM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 2 months, Meridian Bioscience has returned 19.47% as of today's recent price of $20.43.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bioline unveils EPIK Kits in aid of epigenetic researchers
M2 - Wed Feb 19, 5:25AM CST
Bioline, a wholly-owned subsidiary of Meridian Bioscience Inc (NasdaqGS:VIVO), a US-based life science company, reported on Tuesday the launch of the first kits in the new EPIK product range: the EPIK Fast Quantification Kit and EPIK Amplification Kit.
Bioline Launches New Products for Epigenetics Research
Business Wire - Tue Feb 18, 5:00AM CST
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), announces that it has entered the rapidly growing Epigenetics field, with the launch of the first kits in the new EPIK(TM) product range; EPIK(TM) Fast Quantification Kit and EPIK(TM) Amplification Kit.
Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Tue Feb 18, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/tc2bz6/hospital_acquired) has announced the addition of the "Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Nosocomial infections, most commonly called as hospital acquired diseases or healthcare associated infections (HAI),are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infections has been observed worldwide and its morbidity rate is rapidly growing. Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients worldwide are highly susceptible to nosocomial infection. Aging of population is one of the major factors that has increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality globally. Contraction of nosocomial infection prolongs hospital stay of patients and ultimately the cost to the patients as well as the hospital increases. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thus creating a challenge for healthcare professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriate treatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market. Nosocomial infections are mainly categorized into six types depending on the kind of infection, namely, hospital acquired pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA (Methicillin-resistant Staphylococcus aureus)infection and other miscellaneous variants which include gastro intestinal infection, cardiovascular infections, respiratory infections and infections related to joints. Occurrence of hospital acquired UTI is highest in all types of nosocomial infections,leading to the highest market share by revenue of hospital acquired UTI testing segment in the overall HAI testing market. Geographically, North America dominates the global hospital acquired disease testing market and is followed by Europe. Government initiatives to control and prevent nosocomial infection in these regions and their rigorous implementation to reduce the disease morbidity rate is driving the growth of nosocomial infection testing market. Asia-Pacific is a lucrative market for HAI testing owing to increased incidence of hospital acquired disease testing in countries like China and India and the growing need to reduce healthcare expenditure by both, the healthcare institutions and patients equally. Contribution of Asian countries to the hospital acquired disease testing market is expected to increase further as the medical tourism industry flourishes in this region. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles Companies Mentioned - Abbott Laboratories - Alere - bioMerieux - Becton, Dickinson and Company - Cantel Medical - Cepheid - Diatherix Laboratories - F. Hoffman-La Roche - Gen-Probe - Life Technologies - Meridian Bioscience - Nordion - Qiagen For more information visit http://www.researchandmarkets.com/research/tc...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Meridian Bioscience Has Returned 18.6% Since SmarTrend Recommendation (VIVO)
Comtex SmarTrend(R) - Tue Feb 11, 9:36AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 4 weeks, Meridian Bioscience has returned 18.57% as of today's recent price of $20.66.
Bioline Launches High Performance SensiFAST(TM) cDNA Synthesis Kit
Business Wire - Fri Feb 07, 6:00AM CST
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFAST(TM) cDNA synthesis kit. Powered by a newly developed Reverse Transcriptase enzyme with enhanced properties and in combination with the unique TransAmp(TM) buffer; SensiFAST(TM) cDNA synthesis kit is the choice for scientists who need consistent, unbiased, first-strand cDNA synthesis necessary for high sensitivity real-time PCR experiments.
Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019
M2 - Wed Feb 05, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3x48h/enteric_disease) has announced the addition of the "Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019" report to their offering. Various microbes responsible for enteric infections include salmonella, shigella, rotavirus, norovirus, c. difficile, cryptosporidium, vibrio and campylobacter. These diseases may range from asymptomatic to having mild to severe symptoms such as bloody diarrhea, abdominal cramps, stool containing blood or pus, fever and weight loss. Incubation period varies from few days to few weeks depending on the disease and severity. In order to reduce the chance of developing complications, these diseases needed to be diagnosed early. Earlier, diagnosis of enteric diseases relied on culture results of stool specimen that involved identification of causative pathogens in a culture medium. However, the trend is now shifting from culture methods to other diagnostic methods owing to limitations associated with culture tests. Major drawbacks associated with culture tests include high cost, labor intensive, requires sophisticated laboratory and a skilled person to perform the diagnosis. On the other hand, enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) has made enteric infection diagnosis easy and fast. In developed regions such as North America and Europe, PCR based diagnosis is most recommended testing method for enteric diseases as it offers high sensitivity and specificity and is considered as easy, accurate, rapid and reliable method of diagnosis. Latest introductions in MALDI-TOF have also been developed for rapid diagnosis of whole organisms without destruction of infection sample. Asia-Pacific accounting for more than 50% of the total global population represents the most profitable market for enteric disease testing in terms of growth and potential. Key Topics Covered: 1 Preface 2 Executive Summary 3 Enteric Disease Testing Market Overview 4 Global Enteric Disease Testing Market 5 Global Enteric Disease Testing Market, By Geography, 2011 - 2019 6 Key Player Analysis for Enteric Disease Testing Market, 2012 7 Company Profiles Companies Mentioned: - Alere - Becton Dickinson & Company - Biomerica - Biomerieux - Bio-Rad - Cepheid - Coris Bioconcept - Diasorin - Meridian Bioscience - Quest Diagnostics - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/v3...ic_disease
Meridian Bioscience Reports First Quarter 2014 Operating Results, Declares Increased Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Wed Jan 22, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
Meridian Expands Biz, Shares Fall on Weak Q1 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 2:30PM CST
Meridian expands business in Singapore. However, share price falls as it announces weak preliminary first-quarter fiscal 2014 operating results.
Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business
Business Wire - Wed Jan 15, 4:59PM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced weaker than expected preliminary operating results for the first quarter ended December 31, 2013.
FDA Okays VIVO's Flu Assay, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 4:05PM CST
Meridian's Flu Assay gets the FDA approval
Bioline Expands into Singapore
Business Wire - Tue Jan 14, 5:59AM CST
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an office in Singapore to support and grow the Bioline business in Singapore and in Asia.
Meridian Bioscience Inc awarded special FDA's 510(k) clearance for TRU FLU for avian H7N9 influenza strain
M2 - Mon Jan 13, 6:01AM CST
Life science company Meridian Bioscience Inc (NasdaqGS:VIVO) reported on Friday the receipt of FDA clearance for TRU FLU assay for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013.
Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU(R) to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim
Business Wire - Fri Jan 10, 12:59PM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the company's TRU FLU(R) assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU(R) is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.
Shares of VIVO Down 13.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 12, 9:59AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 2 months, Meridian Bioscience has returned 13.76% as of today's recent price of $21.88.
Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018 Out Now
M2 - Fri Mar 07, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/4hmks6/global_isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technologies Market 2014-2018" report to their offering. The analysts forecast the Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17.49 percent over the period 2013-2018. One of the key factors contributing to this market growth is the technological advances being made in this domain. The Global Isothermal Nucleic Acid Amplification Technologies market has also been witnessing an increase in the miniaturization of nucleic acid-based diagnostics. However, the tough competition from PCR-based diagnostics could pose a challenge to the growth of this market. The key vendors dominating this space are Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Corp. The other vendors mentioned in the report are Alere Inc., Axxin Pvt Ltd., Eiken Chemical Co. Ltd., Great Basin Corp., Lucigen Corp., Meridian Bioscience Inc., New England Biolabs Inc., and Optigene Ltd. Commenting on the report, an analyst from the team said: The Molecular Diagnostics industry is experiencing a rapid shift toward an increase in the process automation and integration of sample analysis in single miniaturized devices. Miniaturization offers scope for reduced sample volume, enabling the end-user to automate and analyze the sample. Among all the diagnostic methods, nucleic acid testing remains the method with the most potential for conducting analysis in miniaturized devices. Although PCR is one of the standard techniques for conducting amplification reaction, the method is quite complex due to the need for repeated thermo cycling and cooling, and it consumes more energy in the process. As an alternative to PCR, isothermal nucleic amplification circumvents the need for repeated denaturation and cooling as the amplification reaction occurs under isothermal conditions. This greatly aids in the design of microfluidic chips for conducting molecular diagnostics. Most of these microfluidic devices adopting isothermal nucleic acid amplification methods are in the R&D phase. It is expected that the increase in miniaturization of nucleic acid-based diagnostics will boost the growth of the market. For more information visit http://www.researchandmarkets.com/research/4h...isothermal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
19.5% Return Seen to Date on SmarTrend Meridian Bioscience Call (VIVO)
Comtex SmarTrend(R) - Tue Mar 04, 5:24PM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 2 months, Meridian Bioscience has returned 19.47% as of today's recent price of $20.43.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bioline unveils EPIK Kits in aid of epigenetic researchers
M2 - Wed Feb 19, 5:25AM CST
Bioline, a wholly-owned subsidiary of Meridian Bioscience Inc (NasdaqGS:VIVO), a US-based life science company, reported on Tuesday the launch of the first kits in the new EPIK product range: the EPIK Fast Quantification Kit and EPIK Amplification Kit.
Bioline Launches New Products for Epigenetics Research
Business Wire - Tue Feb 18, 5:00AM CST
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), announces that it has entered the rapidly growing Epigenetics field, with the launch of the first kits in the new EPIK(TM) product range; EPIK(TM) Fast Quantification Kit and EPIK(TM) Amplification Kit.
Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Tue Feb 18, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/tc2bz6/hospital_acquired) has announced the addition of the "Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Nosocomial infections, most commonly called as hospital acquired diseases or healthcare associated infections (HAI),are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infections has been observed worldwide and its morbidity rate is rapidly growing. Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients worldwide are highly susceptible to nosocomial infection. Aging of population is one of the major factors that has increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality globally. Contraction of nosocomial infection prolongs hospital stay of patients and ultimately the cost to the patients as well as the hospital increases. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thus creating a challenge for healthcare professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriate treatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market. Nosocomial infections are mainly categorized into six types depending on the kind of infection, namely, hospital acquired pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA (Methicillin-resistant Staphylococcus aureus)infection and other miscellaneous variants which include gastro intestinal infection, cardiovascular infections, respiratory infections and infections related to joints. Occurrence of hospital acquired UTI is highest in all types of nosocomial infections,leading to the highest market share by revenue of hospital acquired UTI testing segment in the overall HAI testing market. Geographically, North America dominates the global hospital acquired disease testing market and is followed by Europe. Government initiatives to control and prevent nosocomial infection in these regions and their rigorous implementation to reduce the disease morbidity rate is driving the growth of nosocomial infection testing market. Asia-Pacific is a lucrative market for HAI testing owing to increased incidence of hospital acquired disease testing in countries like China and India and the growing need to reduce healthcare expenditure by both, the healthcare institutions and patients equally. Contribution of Asian countries to the hospital acquired disease testing market is expected to increase further as the medical tourism industry flourishes in this region. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles Companies Mentioned - Abbott Laboratories - Alere - bioMerieux - Becton, Dickinson and Company - Cantel Medical - Cepheid - Diatherix Laboratories - F. Hoffman-La Roche - Gen-Probe - Life Technologies - Meridian Bioscience - Nordion - Qiagen For more information visit http://www.researchandmarkets.com/research/tc...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Meridian Bioscience Has Returned 18.6% Since SmarTrend Recommendation (VIVO)
Comtex SmarTrend(R) - Tue Feb 11, 9:36AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on January 16th, 2014 at $25.37. In approximately 4 weeks, Meridian Bioscience has returned 18.57% as of today's recent price of $20.66.
Bioline Launches High Performance SensiFAST(TM) cDNA Synthesis Kit
Business Wire - Fri Feb 07, 6:00AM CST
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFAST(TM) cDNA synthesis kit. Powered by a newly developed Reverse Transcriptase enzyme with enhanced properties and in combination with the unique TransAmp(TM) buffer; SensiFAST(TM) cDNA synthesis kit is the choice for scientists who need consistent, unbiased, first-strand cDNA synthesis necessary for high sensitivity real-time PCR experiments.
Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019
M2 - Wed Feb 05, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3x48h/enteric_disease) has announced the addition of the "Concise Analysis on the International Enteric Disease Testing Market - Forecasts to 2019" report to their offering. Various microbes responsible for enteric infections include salmonella, shigella, rotavirus, norovirus, c. difficile, cryptosporidium, vibrio and campylobacter. These diseases may range from asymptomatic to having mild to severe symptoms such as bloody diarrhea, abdominal cramps, stool containing blood or pus, fever and weight loss. Incubation period varies from few days to few weeks depending on the disease and severity. In order to reduce the chance of developing complications, these diseases needed to be diagnosed early. Earlier, diagnosis of enteric diseases relied on culture results of stool specimen that involved identification of causative pathogens in a culture medium. However, the trend is now shifting from culture methods to other diagnostic methods owing to limitations associated with culture tests. Major drawbacks associated with culture tests include high cost, labor intensive, requires sophisticated laboratory and a skilled person to perform the diagnosis. On the other hand, enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) has made enteric infection diagnosis easy and fast. In developed regions such as North America and Europe, PCR based diagnosis is most recommended testing method for enteric diseases as it offers high sensitivity and specificity and is considered as easy, accurate, rapid and reliable method of diagnosis. Latest introductions in MALDI-TOF have also been developed for rapid diagnosis of whole organisms without destruction of infection sample. Asia-Pacific accounting for more than 50% of the total global population represents the most profitable market for enteric disease testing in terms of growth and potential. Key Topics Covered: 1 Preface 2 Executive Summary 3 Enteric Disease Testing Market Overview 4 Global Enteric Disease Testing Market 5 Global Enteric Disease Testing Market, By Geography, 2011 - 2019 6 Key Player Analysis for Enteric Disease Testing Market, 2012 7 Company Profiles Companies Mentioned: - Alere - Becton Dickinson & Company - Biomerica - Biomerieux - Bio-Rad - Cepheid - Coris Bioconcept - Diasorin - Meridian Bioscience - Quest Diagnostics - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/v3...ic_disease
Meridian Bioscience Reports First Quarter 2014 Operating Results, Declares Increased Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Wed Jan 22, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
Meridian Expands Biz, Shares Fall on Weak Q1 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 2:30PM CST
Meridian expands business in Singapore. However, share price falls as it announces weak preliminary first-quarter fiscal 2014 operating results.
Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business
Business Wire - Wed Jan 15, 4:59PM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced weaker than expected preliminary operating results for the first quarter ended December 31, 2013.
FDA Okays VIVO's Flu Assay, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 4:05PM CST
Meridian's Flu Assay gets the FDA approval
Bioline Expands into Singapore
Business Wire - Tue Jan 14, 5:59AM CST
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an office in Singapore to support and grow the Bioline business in Singapore and in Asia.
Meridian Bioscience Inc awarded special FDA's 510(k) clearance for TRU FLU for avian H7N9 influenza strain
M2 - Mon Jan 13, 6:01AM CST
Life science company Meridian Bioscience Inc (NasdaqGS:VIVO) reported on Friday the receipt of FDA clearance for TRU FLU assay for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013.
Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU(R) to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim
Business Wire - Fri Jan 10, 12:59PM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the company's TRU FLU(R) assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU(R) is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.
(0)
(0)Meridian Bioscience Inc. (VIVO) Stock Research Links
Scroll down for more posts ▼